Journals / ARTEMİS / 2004 / Cilt: 5 - Sayı: 2

Komplet mol hidatiformda değişmiş arjinin metabolizması

Altered arginine metabolism in complete hydatidiform mole

Journal
ARTEMİS
Pages
131–134
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: The significance of this apparent breakdown in the co-regulation of nitric oxide synthase and arginase in the pathophysiology of complete hydatidiform mole remains to be determined.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Nitric oxide is considered a key inhibitor of cellular proliferation and inducer of differentiation in vitro, and some hyperproliferative conditions have been shown to involve decreased production of nitric oxide due to overexpression of arginase.
📊
Key Findings & Data:This study set out to investigate a possible role for such a process in complete hydatidiform mole.MATERIALS-METHODS: Plasma arginase levels and plasma nitric oxide levels were measured in 29 patients with complete hydatidiform mole and in 27 healthy pregnant women.
💡
Conclusion & Impact:CONCLUSION: The significance of this apparent breakdown in the co-regulation of nitric oxide synthase and arginase in the pathophysiology of complete hydatidiform mole remains to be determined.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: Nitric oxide is considered a key inhibitor of cellular proliferation and inducer of differentiation in vitro, and some hyperproliferative conditions have been shown to involve decreased production of nitric oxide due to overexpression of arginase. This study set out to investigate a possible role for such a process in complete hydatidiform mole.MATERIALS-METHODS: Plasma arginase levels and plasma nitric oxide levels were measured in 29 patients with complete hydatidiform mole and in 27 healthy pregnant women. RESULTS: Compared with healthy pregnant controls, patients with complete hydatidiform mole had significantly higher mean plasma levels of nitric oxide (36.78±7.97 vs 28.60±7.32 µmol/L; p = 0.001), and -though not significantly- higher plasma levels of arginase activity (16.72±6.03 vs 11.26±5.11 U/g protein; p = 0.085). CONCLUSION: The significance of this apparent breakdown in the co-regulation of nitric oxide synthase and arginase in the pathophysiology of complete hydatidiform mole remains to be determined.

Özet

Amaç: Nitrik oksitin in vitro hücresel proliferasyon inhibitörü ve diferansiasyon indükleyicisi olduğu düşünülmektedir. Bazı hiperproliferatif durumlarda, arjinazın artışına bağlı olarak nitrik oksit üretiminde azalma olduğu gösterilmiştir. Bu çalışma, komplet mol hidatiformda bu sürecin olası rolünü araştırmak için düzenlenmiştir. Materyal ve Metot: Yirmi yedi sağlıklı gebe kadın ve 29 komplet mol hidatiform hastasında plazma arjinaz ve nitrik oksit düzeyleri ölçüldü. Sonuçlar: Sağlıklı gebe kontrol grubuyla karşılaştırıldığında, komplet mol hidatiform hastalarında ortalama plazma nitrik oksit düzeyleri anlamlı olarak yüksek (36.78±7.97 vs 28.60±7.32 µmol/L; p = 0.001) ve plazma arjinaz düzeyleri, istatistiksel olarak anlamlı olmasa da yüksek (16.72±6.03 vs 11.26±5.11 U/g protein; p = 0.085) bulunmuştur. Tartışma: Arjinaz ve nitrik oksit sentaz koregülasyonundaki belirgin bozukluğun, komplet mol hidatiform fizyopatolojisindeki önemi araştırılmalıdır.

🔖

Cite This Article

KOÇYİĞİT, A., HARMA, M., DEMİR, N., GÜNGEN, N., KÖYLÜ, A. A., HARMA, M. (2022). Komplet mol hidatiformda değişmiş arjinin metabolizması. ARTEMİS, Cilt: 5 - Sayı: 2, 131–134. https://ajindex.com/articles/449478

References (13)

  1. Li HW, Tsao SW, Cheung AN. Current understandings of the molecular ge- netics of gestational trophoblastic diseases. Placenta. 2002;23(1):20-31
  2. Jude EB, Boulton AJ, Ferguson MW, Appleton I. The role of nitric oxide synthase isoforms and arginase in the pathogenesis of diabetic foot ulcers: possible modulatory effects by transforming growth factor beta 1. Diabetologia. 1999;42(6):748-57
  3. Rodriguez S, Richert L, Berthelot A. Increased arginase activity in aorta of mineralocorticoid-salt hypertensive rats. Clin Exp Hypertens. 2000;22(1):75-85
  4. Waddington SN, Mosley K, Cook HT, Tam FW, Cattell V. Arginase AI is upregulated in acute immune complex-induced inflammation. Biochem Biophys Res Commun. 1998;9;247(1):84-7
  5. Wei LH, Jacobs AT, Morris SM Jr, Ignarro LJ. IL-4 and IL-13 upregulate arginase I expression by cAMP and JAK/STAT6 pathways in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2000;279(1):C248-56
  6. Chang CI, Zoghi B, Liao JC, Kuo L. The involvement of tyrosine kinases, cyclic AMP/protein kinase A, and p38 mitogen-activated protein kinase in IL-13-mediated arginase I induction in macrophages: its implications in IL- 13-inhibited nitric oxide production. J Immunol. 2000;165(4):2134-41. 7. de Belder AJ, Radomski MW. Nitric oxide in the clinical arena. J Hypertens. 1994;12(6):617-24
  7. Brennan PA., Downie IP, Langdon JD, Zaki GA. Emerging role of nitric oxide in cancer. Br J Oral Maxillofac Surg. 1999;37(5):370-3
  8. Sanyal M, Nag TC, Das C. Localization of nitric oxide synthase in human trophoblast cells: role of nitric oxide in trophoblast proliferation and differentiation. Am J Reprod Immunol. 2000;43(2):70-7
  9. Ramsay B, Sooranna SR, Johnson MR. Nitric oxide synthase activities in human myometrium and villous trophoblast throughout pregnancy. Obstet Gynecol. 1996;87(2):249-53
  10. Ariel I, Hochberg A, Shochina M. Endothelial nitric oxide synthase immunoreactivity in early gestation and in trophoblastic disease. J Clin Pathol. 1998;51(6):427-31
  11. Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V, Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res. 1994;54(5):1352-4
  12. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S. Nitric oxide synthase activity in human breast cancer. Br J Cancer. 1995;72(1):41-4
  13. Moriyama A., Masumoto A, Nanri H, Tabaru A, Unoki H, Imoto I, Ikeda M, Otsuki M. High plasma concentrations of nitrite/nitrate in patients with hepa